A61K 38/26
Glucagons
A61K38/26 (Glucagons) appears on 1,279 US grants and 2,683 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,279
- Published applications
- 2,683
- Assignees
- 745
- Inventors
- 3,518
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 2 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 5 | 0 |
| 1993 | 3 | 0 |
| 1994 | 2 | 0 |
| 1995 | 5 | 0 |
| 1996 | 4 | 0 |
| 1997 | 8 | 0 |
| 1998 | 7 | 0 |
| 1999 | 8 | 0 |
| 2000 | 2 | 0 |
| 2001 | 11 | 8 |
| 2002 | 8 | 22 |
| 2003 | 14 | 32 |
| 2004 | 7 | 41 |
| 2005 | 10 | 29 |
| 2006 | 18 | 53 |
| 2007 | 14 | 48 |
| 2008 | 9 | 44 |
| 2009 | 19 | 58 |
| 2010 | 23 | 79 |
| 2011 | 22 | 68 |
| 2012 | 42 | 88 |
| 2013 | 44 | 116 |
| 2014 | 63 | 118 |
| 2015 | 67 | 146 |
| 2016 | 77 | 121 |
| 2017 | 89 | 158 |
| 2018 | 99 | 131 |
| 2019 | 87 | 173 |
| 2020 | 80 | 156 |
| 2021 | 92 | 129 |
| 2022 | 65 | 167 |
| 2023 | 63 | 150 |
| 2024 | 54 | 203 |
| 2025 | 86 | 193 |
| 2026 | 69 | 152 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Protein with anti-inflammatory properties6 Oct 2026US 12,753,214 B2Revolo Biotherapeutics Limited
- Implants for release of lipophilic or amphiphilic pharmaceutical substances29 Sep 2026US 12,746,275 B2ReacX Pharmaceuticals, Inc.
- Manufacture, formulation and dosing of apraglutide29 Sep 2026US 12,746,276 B2VectivBio AG
- Pharmaceutical formulations22 Sep 2026US 12,741,013 B2Novo Nordisk A/S
- Pharmaceutical formulations22 Sep 2026US 12,741,014 B2Novo Nordisk A/S
- Fgf21 compound / glp-1r agonist combinations with optimized activity ratio8 Oct 2026US 2026/0306587 A1Sanofi
- Compositions and uses of glp-1-gip receptor agonists8 Oct 2026US 2026/0306588 A1Maison Blaise Labs, LLC
- Alk7 combination treatments8 Oct 2026US 2026/0306628 A1
- Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof8 Oct 2026US 2026/0308529 A1Imagine Pharma LLC
- Water-soluble biomolecular glass microneedle and preparation method thereof1 Oct 2026US 2026/0294794 A1Institute of Process Engineering, Chinese Academy of Sciences
Most cited
By later US patents
- Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity273US 6,191,102 B1Eli Lilly and Company · 2001
- Insulinotropic hormone271US 5,118,666 AThe General Hospital Corporation · 1992
- Insulinotropic hormone GLP-1 (7-36) and uses thereof270US 5,614,492 AThe General Hospital Corporation · 1997
- Insulinotropic hormone253US 5,120,712 AThe General Hospital Corporation · 1992
- Derivatives of GLP-1 analogs248US 6,268,343 B1Novo Nordisk A/S · 2001